How Should We Treat Severe Malaria in the Setting of Artemisinin Partial Resistance?

Philip J. Rosenthal, Moses R. Kamya, Ruth Namazzi, Chandy C. John · 2026

Read How Should We Treat Severe Malaria in the Setting of Artemisinin Partial Resistance? by Philip J. Rosenthal, Moses R. Kamya, Ruth Namazzi, Chandy C. John (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13550749.txt.

Description

Severe malaria care rests on a drug family that is losing some of its punch in parts of Africa. Philip J Rosenthal, Moses R Kamya, Ruth Namazzi, and Chandy C John review the state of care in a 2026 paper. Two recent studies in Uganda looked at children in hospital with severe malaria. All were treated with the standard drug given by vein.

Children with resistant parasites cleared the parasites more slowly than other children. Yet death rates, hospital stay length, and later fever or readmission did not differ between the groups. The authors conclude that the standard vein treatment should stay the norm for severe malaria in sub-Saharan Africa for now. They also urge continued study as resistance spreads. The review speaks to doctors who treat severe cases.

Catalog record

CREATORPhilip J. Rosenthal, Moses R. Kamya, Ruth Namazzi, Chandy C. John
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE8 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13550749

Browse the full library · About the Tower of Babel